Skip to main content
BWXT $173.22 +1.68%
BWXT logo

BWXT · BWX Technologies, Inc.

Track BWXT — free
$173.22 +2.87 (+1.68%) At close · Aug 14
Market Cap
$15.87B
Shares
91.62M
All earnings calls

Earnings call · FY2025 Q4

BWX Technologies, Inc. Q4 FY2025 Earnings Call

BWX Technologies, Inc. Q4 FY2025 Earnings Call

Concluded Feb 23, 2026 Audio replay
Feb 23, 2026 44:28 69 turns
Period
FY2025 Q4
Runtime
44:28
Sources
4 artifacts

Executive readout · one minute

What matters this quarter

BWXT delivered record 2025 results with revenue up 18%, adjusted EBITDA up 15%, EPS up 20%, and free cash flow up 16%, all exceeding initial guidance, while backlog grew 50% year-over-year to $7.3 billion driven by naval propulsion, special materials, and commercial nuclear awards. The company initiated 2026 guidance for non-GAAP EPS of $4.55-$4.70, adjusted EBITDA of $645-$660 million, and free cash flow of $305-$320 million.

Backlog and Revenue Growth 20 Advanced Fuels & Micro-reactors 16 Government/Naval Propulsion 13 M&A Integration / Conetrix 8 Medical / Tech 99 8 Special Materials / Uranium Enrichment 8

Management tone

Confident

Net tone +70 · low hedging

Grounding quotes
  • “We closed out a record 2025 with another a strong quarter of results that were ahead of our expectations for the full year.”
  • “Backlogged into 2025 at $1.7 billion, up 85% compared to last year, and up 60% sequentially, driven by equipment for can-do refurbishments in Canada and other international markets and design awards for SMR components to various reactor OEMs.”
  • “I would also say that, you know, as the market really starts to warm up and we start to see real capacity and constraint, I think we'll be more competitive and we'll have more pricing power. So I'm optimistic about all of it.”
  • “We have not submitted to the FDA yet. And I have, frankly, imperfect clarity around that because of these product quality issues that we're having to sort through.”

Forward guidance

4 guided metrics

Management's latest ranges and targets are included below.

Research coverage

4 live sources

Switch sources without leaving this page or losing your listening position.

Revenue $885.84M +18.7% YoY
Diluted EPS $1.01 +31.2% YoY
Net income $92.99M +30.9% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

Key takeaways

What improved, and what deserves a closer read.

Constructive signals

  • Backlog of $7.3 billion, up 50% year-over-year, supporting robust growth outlook
  • Commercial operations revenue grew 95% in Q4 and 63% for the full year, with commercial backlog up 85% to $1.7 billion
  • 2026 guidance calls for adjusted EBITDA of $645-$660 million and non-GAAP EPS of $4.55-$4.70, implying continued growth
  • Strategic wins include the $1.6 billion high-purity depleted uranium contract, $151 billion Golden Dome MDA award, and owner's engineer role on Bulgaria's Kozloduy AP1000 project
  • Full-year free cash flow of $295.3 million, up 16%, with operating cash flow up 17%
  • BWXT Medical surpassed $100 million in annual revenue, up about 20%, with double-digit diagnostic isotope growth

Risks & pressure points

  • Government operations Q4 revenue down 1% and adjusted EBITDA down 5% year-over-year
  • Q4 government operating income fell 8% to $90.3 million from $98.1 million
  • 2026 effective tax rate expected to rise to approximately 22% from 20.4% in 2025
  • 2026 CapEx guided to about 6% of sales, higher than 2025's 5.8%
  • Tech 99 FDA submission not yet made due to product quality issues, and any 2026 Tech 99 revenue was not included in guidance
  • Canadian Competition Bureau investigation into the Conetrix acquisition remains ongoing with no resolution noted

Key moments

Jump directly to management's words in the synchronized transcript.

Forward guidance

From the 8-K filed Feb 23, 2026.

Metric Guided
Revenue table
Year Ending December 31, 2026
$3.75B
Adjusted EBITDA table
Year Ending December 31, 2026
$645M – $660M
Free Cash Flow table
Year Ending December 31, 2026
$305M – $320M
Non-GAAP Earnings Per Share table
Year Ending December 31, 2026
$4.55 – $4.70

Quarter detail

How the reported period landed and where the business moved.

Capital returned

Dividend / share
$0.27
Full-screen source Call document